Answers are grounded in this paper and cite their sources.
Retrospective cohort study identifies key predictors of cardiovascular events post-allogeneic hematopoietic stem cell transplantation, suggesting targeted prevention strategies.
Background Cardiovascular (CV) complications present a significant risk for patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). However, comprehensive data on these risks within large cohorts remain limited. Purpose To identify predictors of CV events in a large cohort of AHSCT patients. Methods We conducted a retrospective monocentric longitudinal cohort study including all consecutive patients with hematologic malignancies who underwent AHSCT between July 2011 and December 2020. Data were extracted from electronic medical records, including demographic, clinical, and transplant-specific variables. The primary outcome was defined as a composite of CV events, including CV death, heart failure (HF), rhythm/conduction disorders, acute arterial events, venous thromboembolism (VTE), and myopericarditis. Predictors of CV events were analyzed using Cox proportional hazards regression and Fine-and-Gray subdistribution hazard models. Results Among 1,027 patients recruited (age 45±16 years, 62% male), 30% experienced CV events after a median (interquartile range) follow-up of 4 (1-7) years. The median time to the first event was 8 months, with a median age at the first event of 53 (41-61) years. Key predictors for early MACE (≤100 days) included age, hypertension, history of HF, cardiotoxicity related to oncologic therapies, and high-dose of cyclophosphamide. For late MACE (>100 days), predictors included age, hypertension, history of VTE, supraventricular tachycardia, HF, cardiotoxicity related to oncologic therapies, previous liposomal anthracycline exposure, and high-risk Sorror category. Conclusions Identifying key predictors of CV events is crucial for developing targeted surveillance and preventive strategies, thereby improving management and outcomes for AHSCT patients.
No takes yet. Share an insight, caveat, or question.
Sibilia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: